Pharming’s Ruconest for HAE granted European Marketing Authorization

Biotech company Pharming Group has announced that the European Commission has granted Pharming Marketing Authorization for its lead product Ruconest for the treatment of acute attacks of Hereditary Angioedema.

Biotech company Pharming Group (www.pharming.com) has announced that the European Commission has granted Pharming Marketing Authorization for its lead product Ruconest for the treatment of acute attacks of Hereditary Angioedema (HAE). Pharming will now receive a €5 million milestone payment from marketing and distribution partner Sobi.
 
Following the unanimous positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP), Ruconest’s Marketing Authorization has now been ratified by the European Committee.
 
Patients suffering from HAE experience unpredictable, painful and debilitating attacks, due to reduced levels of C1 inhibitor, resulting in intense swelling of parts of the body (for example, face, throat, abdomen) which can last up to five days if left untreated. Ruconest is a recombinant version of the human C1 inhibitor protein, produced by Pharming’s proprietary transgenic technology. As publis